Pherin Pharmaceuticals: Vistagen to Acquire Pherin Pharmaceuticals

Vistagen (Nasdaq: VTGN), a San Francisco, CA-based clinical-stage biopharmaceutical company, acquired Pherin Pharmaceuticals, a San Francisco, CA-based clinical-stage drug development company. The companies have entered into a definitive agreement under which Vistagen will acquire Pherin for approximately 12.4 million shares of Vistagen common stock and a nominal amount of cash. The deal is subject to customary [...]The post Vistagen to Acquire Pherin Pharmaceuticals appeared first on FinSMEs.